Erasca Partners with Tango Therapeutics to Test Cancer Drug Combination
Event summary
- Erasca and Tango Therapeutics will collaborate on a Phase 1/2 clinical trial combining ERAS-0015 and vopimetostat for MTAP-deleted pancreatic and NSCLC cancers.
- Erasca will supply ERAS-0015 at no cost, while Tango will sponsor the trial.
- The trial targets MTAP-deleted RAS-mutant cancers, where treatment options are limited.
- ERAS-0015 has shown early clinical responses at low doses in multiple tumor types.
The big picture
This collaboration aligns with the broader trend in oncology toward combination therapies targeting specific genetic mutations. The focus on MTAP-deleted cancers highlights the growing emphasis on precision medicine, where tailored treatments aim to address high unmet medical needs. The success of this trial could set a precedent for similar partnerships in the biotech sector.
What we're watching
- Clinical Efficacy
- How the combination of ERAS-0015 and vopimetostat will perform in Phase 1/2 trials, particularly in MTAP-deleted cancers.
- Regulatory Pathway
- The pace at which the trial progresses and whether it meets regulatory milestones for approval.
- Commercial Strategy
- Whether Erasca and Tango can leverage this collaboration to expand their market reach in precision oncology.
Related topics